Dr Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the
biology of and treatment for prostate cancer. Dr. Ryan earned a BA in Philosophy, magna cum
laude, from Marquette University and MD from University of Wisconsin Medical School. He
trained at the University of Wisconsin Hospital and Clinics, and at Memorial Sloan Kettering
Cancer Center. As faculty at the University of California-San Francisco, he was named the
Thomas Perkins Distinguished Professor in Cancer Research and was Associate Director of the
Helen Diller Family Comprehensive Cancer Center. He has received research funding from the
National Institutes of Health, the Department of Defense Prostate Cancer Research Program,
and the Prostate Cancer Foundation. Dr Ryan led a substantial proportion of the development of
Abiraterone, now a standard of care for prostate cancer patients worldwide, through leadership
of clinical trials at Phases I, II and III which resulted in FDA approval. Dr. Ryan is a past Chair of
the National Cancer Institute’s GU Steering Committee’s Prostate Cancer Task Force. From
2021 to 2024 Ryan served as the CEO of the Prostate Cancer Foundation. He serves as
Medical Director of the Prostate Cancer Clinical Trials Consortium and is a member of the
Advanced Prostate Cancer Consensus Conference. Ryan has published over 240 articles and
chapters in the world’s leading medical journals. He is the author of the book The Virility
Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In,
and the founder and Co-host of the podcast The Good News About Cancer. He is currently a
member of the faculty at Memorial Sloan Kettering Cancer Center in New York.